Gonadal Disorders

Male reproductive physiology

Ola Mohammed Al-sallal

Sexual differentiation

- Genetic sex determined by the sex chromosomes, either XX or XY
- Gonadal sex is defined by presence of testes or ovaries
- Phenotypic sex is defined by the hormonal output of the gonads


Male phenotype <<

testes secretes testosterone which stimulate differentiation of wolffian ducts

AMH secreted by sertoli cells in testes cause mullerian ducts atrophy

Female phenotype<<


Differentiation of wolffian ducts into the internal female genital tract Development of external genital tract dosen't require any hormones




The male gonads are testes which have 2 functions:

1. Spermatogenesis


80% of testes is seminiferous tubules and 20% is connective tissue




- 1. Provide nutrition to sperm
- Blood testes barrier
- 3. Secrete aqueous fluid which help transporting sperms
- 4. Secrete androgen binding protein



Synthesize and secrete testosterone which has endocrine and paracrine effects





2. Synthesis and secretion of testosterone

The steroidogenic pathways in testes similar to those in adrenal cortex except:

<testes lack 21-B hydroxylase and 11-B hydroxylase for MC and GC synthesis <testes has additional enzyme 17B-hydroxysteroid dehydrogenase that converts androstenedione to testosterone

* In some tissues dihydrotestosterone is the active androgen(alpha reductase convert testosterone to Dihydrotestosterone)

Mediated by Testosterone


Differentiation of
epididymis, vas
deferens, and seminal
vesicles
Increased muscle mass
Pubertal growth spurt
Cessation of pubertal

growth spurt
(epiphyseal closure)
Growth of penis and
seminal vesicles
Deepening of voice
Spermatogenesis
Negative feedback on
anterior pituitary
Libido

Mediated by Dihydrotestosterone

Differentiation of penis, scrotum, and prostate Male hair pattern Male pattern baldness Sebaceous gland activity Growth of prostate

Regulation of the testes




Female reproductive physiology


- The female gonads are the ovaries, which, together with the uterus and fallopian tubes constitute the female reproductive tract
- Ovary has 3 zones>>
- 1. The cortex is the outer and largest .it is lined by germinal epithelium and contains all the oocytes which is enclosed in a follicle
- 2. The medulla is the middle zone and is a mixture of cell types
- 3. Hilum which contains blood vessels and lymphatics

Functional unit of the ovaries is the single ovarian follicle which compromise one germ cell surrounded by endocrine cells, when fully developed it serves several critical roles


The ovaries have 2 functions:

1.Oogenesis





2. Secretion of female sex hormones



Estrogen and progesterone function in a coordinated fashion to support female reproductive activity including >>development of the ovum, development and maintenance of corpus luteum, maintenance of pregnancy and breast preparation for lactation


Over the menstrual cycle estrogen secretion precedes progesterone, preparing target tissues to respond to progesterone, as estrogen upregulates progesterone receptors. Conversely progesterone downregulates estrogen receptors

Regulation of the ovaries

- Like testicular function in male, ovarian function in female is driven by pulsatile activity of hypothalamic pituitary axis
- Every 28 days a sequence of :

follicular development (First 14 days)>>ovulation (In between)>>formation and degeneration of corpus luteum (Last 14 days) is repeated in menstrual cycle

- ☐Granulosa cells are the only ovarian cells with FSH receptors. FSH stimulates growth of granulosa cells in 1ry follicles and stimulate estradiol synthesis
- LH levels in blood increase sharply just prior to ovulation inducing rupture of the dominant follicle. Also stimulates luteinization



 Inhibin is produced by granulosa cells.
 As in the testes it inhibit FSH secretion

Activin is also produced by granulosa cells and stimulate FSH secretion

Actions of estrogen and progesterone

TABLE 10.2 Actions of Estrogens on Target Tissues

Maturation and maintenance of uterus, fallopian tubes, cervix, and vagina

Responsible at puberty for the development of female secondary sex characteristics

Required for development of the breasts

Responsible for proliferation and development of ovarian granulosa cells

Up-regulation of estrogen, progesterone, and LH receptors

Negative and positive feedback effects on FSH and LH secretion

Maintenance of pregnancy

Lowering uterine threshold to contractile stimuli

Stimulation of prolactin secretion

Blocking the action of prolactin on the breast

Decreasing LDL cholesterol

Anti-osteoporosis

TABLE 10.3 Actions of Progesterone on Target Tissues

Maintenance of secretory activity of uterus during luteal phase

Development of the breasts

Negative feedback effects on FSH and LH secretion

Maintenance of pregnancy

Raising uterine threshold to contractile stimuli during

Menstrual cycle


• Recurs approximately every 28 days (21-35). The events include:

Development of ovarian follicle and it's oocyte



Preparation of the reproductive system to receive fertilized ovum


shedding of the end metrial lining if fertilization didn't occur



Done By: Yara Al-Hazaimeh

Is benign proliferation of the glandular tissue of the male breast, is caused by an increase in the ratio of estrogen to androgen activity.

 At least 30% of males will be affected during their life. Since it causes anxiety, psychosocial discomfort and fear of breast cancer, early diagnostic evaluation is important and patients usually seek medical attention.





Associated with increased levels of estradiol and decreased levels of testosterone

- Physiologic changes at puberty senescence
- Endocrine and hormonal disorders
- Systemic disease
- **❖**Neoplasm
- drugs

Table 2. Etiology of gynecomastia


V2200 15000	
Causes	
Physiological factors	Puberty or aging
Endocrine tumors	Testicular, adrenocortical or pituitary tumors, or ectopic hCG-secretion
Endocrine dysfunctions	Hypogonadism, hyperthyroidism, obesity or refeeding
Non-endocrine diseases	Cirrhosis, renal failure or HIV
Drug-induced factors	Medications, anabolic steroids or illicit drugs
Idiopathic factors	

Table 3. Common medications causing gynecomastia41

Type of agent	Medications
Antiandrogens	Bicalutamide, cyproterone, flutamide, finasteride, spironolactone
Antibiotics	Isoniazid, ketoconazole, metronidazole
Antihypertensives	Amlodipine, captopril, enalapril, nifedipine, reserpine, verapamil
Chemotherapeutic agents	Cyclophosphamide, methotrexate
Diuretic	Spironolactone
Gastrointestinal agents	Cimetidine, omeprazole, metodopramide, ranitidine
Hormones	Androgens, anabolic steroids, estrogens, growth hormone
Psychiatric agents	Diazepam, haloperidol, phenothiazine, tricyclic antidepressants
Others	Amiodarone, antiretrovirals, digitalis, domperidone, statins theophylline

Diagnosis of gynecomastia

- 1) Palpable mass of tissue at least 0.5 cm in diameter (usually underlying the nipple).
- 2) The pt position: Patient lies on his back with his hands behind his head.
- 3) The examiner then places his or her thumb and forefinger on each side of the breast and slowly brings them together.




Pubertal gynecomastia

- Occurs in normally-growing infant and pubertal boys that resolves on its own with time is known as <u>physiologic gynecomastia</u>.
- During puberty, levels of these hormones may fluctuate and rise at different levels, resulting in a temporary state in which estrogen concentration is relatively high.
- Gynecomastia caused by transient changes in hormone levels with growth usually disappears on its own within six months to two years.

3- mammographic patterns -representing various degrees and stages of ductal and stromal proliferation

- **❖**Nodular
- Dendritic
- Diffuse glandular


normal



Nodular pattern

• The nodular pattern of gynecomastia is seen in the florid early phase. It begins as an increased number of ducts and epithelial proliferation with edema and cellular fibroblastic stroma. This phase is reversible.

Nodular pattern




Dendritic Pattern

• The dendritic pattern is seen in the fibrotic or late phase.

There are dilated ducts, moderate epithelial proliferation and fibrosis.


Dendritic Pattern



Diffuse glandular pattern

- This pattern is seen in males with very high estrogen levels.
- The image simply looks like small female breasts. .

Diffuse glandular pattern




Pseudogynecomastia - a fatty proliferation of the breasts, without • proliferation of glandular tissue.

Physical findings:


Fingers will not meet any resistance until they reach the nipple. (no discrete mass)

Pseudogynecomastia



		Gynecomastia	Pseudogynecomastia	Breast cancer
	Pathology:	Proliferation of the glandular tissue	Increase in breast fat	Mutation(BRCA1 or BRCA2)
/	Shape:	unilateral/bilateral(+), concentric, rubbery-to-firm disk, mobile, located beneath the areolar area	Diffuse breast enlargement without any subareolar glandular tissue	Unilateral, nontender, fixed, firm to hard, eccentric to the nippleareolar complex
)	Physical findings:	A palpable mass of tissue at least 0.5 cm in diameter	Fingers will not meet any resistance until they reach the nipple. (no discrete mass)	Skin dimpling, nipple discharge & retraction, and regional lymphadenopathy
	Imaging	Not routinely recommended	None	Ultrasonography or Mammography

Male breast cancer



Test	Indication
-Morning serum total testosterone	Middle-aged to older men (2-5%)
-luteinizing hormone (LH) levels -Free or bioavailable testosterone	1)Obese {low sex hormone-binding globulin (SHBG)} 2)Low Morning serum testosterone
-Human Chorionic Gonadotropin (hCG) -LH -Estradiol	1)Recent onset 2)Painful or tender 3)Greater than 5 cm

Line of treatment	Indication	
Stop offending drugs	If the drug is identified as the cause of gynecomastia during the early, proliferative, and often painful phase, stopping it may result in regression of glandular tissue	
Androgens	Male with hypogonadism	
Selective estrogen receptor modulators (SERMs)	Tamoxifen (most common agent) This type of therapy is most often used for severe or painful gynecomastia.	
Surgical intervention	 1) In the late fibrotic stage (after 12 months). 2) Persistent pubertal gynecomastia (lasts until adulthood) 	

HYPOGONADISM

Male

Done By: Aya Al-Ajlouni


Hypogonadism

 Hypogonadism in a male refers to a <u>decrease in</u> one or both of the two major functions of the testes:


<u>sperm production</u> (impaired gamete production)or <u>testosterone production</u> (diminished sex hormone biosynthesis).

These abnormalities can result from disease of the testes (**primary hypogonadism**) or disease of the hypothalamus or pituitary (**secondary hypogonadism**).

 May be a <u>presenting complaint</u> or an <u>incidental</u> <u>finding</u> such as during investigation for subfertility.



- Causes of Primary Hypogonadism (Hypergonadotrophic hypogonadism) in males:
- 1. Congenital abnormalities:
- >Klinefelter syndrome .
- Mutation in the FSH and LH receptor genes.
- >Cryptorchidism .
- >5^a- reductase deficiency.
- >Anorchia /Leydig cell agenesis.



 Causes of Primary Hypogonadism (Hypergonadotrophic hypogonadism) in males:

2. Acquired diseases:


- > Infections, especially mumps orchitis.
- > Testicular torsion .
- > Trauma.
- > Radiation .
- > Environmental toxins .
- > Orchidectomy .
- > Autoimmune damage .
- > Sickle Cell Anemia .
- > Chronic systemic illnesses (Hepatic cirrhosis /Chronic renal failure /AIDS) .

 Causes of Secondary Hypogonadism (Hypogonadotrophic hypogonadism) in males:

1. Acquired:

- >Tumors
- "Functional" gonadotropin deficiency
 -Chronic systemic disease (Asthma /
 Malabsorption/ cystic fibrosis / renal failure
 -Anorexia nervosa, bulimia.
 -Hyperprolactinemia
 -Hypothyroidism, diabetes mellitus, Cushing

 - disease.
- ➤ Infiltrative diseases (Granulomatous diseas Hemochromatosis)




- Causes of Secondary Hypogonadism (Hypogonadotrophic hypogonadism) in males:
- 2. Congenital:
- ➤ Isolated GnRH deficiency:
 - -Kallmann syndrome.
- > Congenital malformations often associated with craniofacial anomalies.
- >Idiopathic forms of multiple anterior pituitary hormone deficiencies.

Clinical features of Hypogonadism

- The clinical features of male hypogonadism depend upon the age of onset, severity of testosterone deficiency, and whether there is a decrease in one or both of the two major functions of the testes: sperm production and testosterone production.
- 1. Decreased sperm production \square Infertility.
- 2. Symptoms are usually related to testosterone deficiency \square Low energy / Low Libido / Erectile Dysfunction / Decreased body/facial hair.

Clinical features of Hypogonadism



***Gynecomastia, tender or not, is more likely to occur in primary than secondary hypogonadism, as is infertility.

Clinical features of Hypogonadism

Lack of Temporal recession of the hairline.




Investigations for Hypogonadism

- Testicular disease may be immediately apparent but basal levels of testosterone, LH and FSH should be measured to distinguish between primary testicular failure and hypothalamic-pituitary disease
- Depending on the causes, semen analysis, chromosomal analysis, pituitary MRI scan, prolactin levels and bone age estimation are required.
 - * Patients with Hypogonadotrophic (Secondary) Hypogonadism should be investigated for pituitary disease.
 - * Patients with Hypergonadotrophic (Primary) Hypogonadism should have the testes examined for cryptorchidism or atrophy, and a karyotype should be performed (to identify Klinefelter's syndrome)

Investigations for Hypogonadism

- Hypogonadism can result from disease of the testes (primary hypogonadism) or disease of the hypothalamus or pituitary (secondary hypogonadism).
 The distinction between these disorders, is made by measurement of the serum concentrations of luteinizing hormone (LH) and follicle-stimulating hormone (FSH):
- 1) The patient has <u>primary hypogonadism</u> if the <u>serum</u> testosterone concentration and/or the <u>sperm count are</u> <u>below normal</u> and the serum LH and/or FSH concentrations are <u>above normal</u>.
- 2) The patient has <u>secondary hypogonadism</u> if the <u>serum testosterone concentration and/or the sperm count</u> <u>are **below normal** and the <u>serum LH and/or FSH concentrations are **normal** or **low**.</u></u>



Treatment of Hypogonadism

> Treatment is testosterone.

- > <u>Testosterone replacement</u> is clearly indicated in younger men with significant hypogonadism to <u>prevent osteoporosis and restore muscle power and libido</u>.
- > Replacement is usually **transdermal gel** or **intramuscular injection**.
- > In gonadotropin deficiency LH and FSH or **pulsatile GnRH** may be used when fertility is desired.

*The role of testosterone replacement to treat the decline in serum testosterone concentration that occurs with aging in men, in the absence of identifiable pituitary or hypothalamic disease, has been unclear. However, results from the Testosterone Trials suggest that testosterone has a beneficial effect on sexual function, mood, possibly walking, bone density, and anemia.

Patient monitoring recommendations


- 1. **Prostate specific antigen (PSA)** should be measured in patients older than 50, because <u>testosterone can aggravate prostatic</u> <u>carcinoma.</u>
- 2. **Hemoglobin** concentration should be monitored in older men, as androgen replacement <u>can cause polycythemia</u>.
- 3. Testosterone therapy <u>impairs spermatogenesis</u> further by suppressing pituitary gonadotropin secretion.

Klinefelter's syndrome (Hypergonadotropic Hypogonadism)

- **Klinefelter's syndrome**: is the most common primary developmental abnormality causing hypogonadism, affecting 1 of every 400-500 males. It's caused by one or more supernumerary X chromosomes.
- > usually associated with a **47xxy karyotype**.
- > There is both a impairment of Leydig cells function and seminiferous tubular dysgenesis.
- > Usually presents in adolescence with poor sexual development, small or undescended testes, gynecomastia or infertility
- > Characteristic long leg length associated with 47xxy, and may be exacerbated by androgen deficiency with lack of epiphyseal closure in puberty.
- > Learning difficulties and behavioral disorders.
- > Increased **risk** of <u>breast cancer</u> and <u>type 2 diabetes</u> in later life.
- > Predisposition for emphysema and bronchiectasis.

Klinefelter's syndrome (Hypergonadotropic Hypogonadism)


- Infertility is the most common symptom.
- 2. Confirmation by chromosomal analysis.
- Treatment is androgen replacement unless testosterone levels are normal.
- 4. No treatment is possible for the abnormal seminiferous tubules and infertility.



- 🐧 Taller than average height
- Reduced Facial Hair
- Reduced Body Hair
- Breast Development (Gynecomastia)
- Feminine Fat Distribution
- Osteoperosis
- Small Testes (Testicular Atrophy)
- Varicose Veins


Turner syndrome Hypergonadotropic Hypogonadism(female)

- Genetic condition that only affects females.
- The condition is caused by an abnormal chromosome and affects about one in every 2,500 baby girls.
- Turner syndrome is typically caused by **nondisjunction**.
- A pair of sex chromosomes fails to separate during the formation of an egg (or sperm), so, when an abnormal egg unites with a normal sperm to form an embryo, that embryo may end up missing one of the sex chromosomes (X rather than XX).
- 45,X.




Turner syndrome Hypergonadotropic Hypogonadism(female)

- Two characteristics that occur in almost all cases of TS. They are:
- 1. Being shorter than average in height.
- A lack of development of the ovaries, leading to infertility.
- One of the missing genes on the X chromosome is the SHOX gene, which is responsible for long bone growth.
- The missing SHOX gene is the reason girls who have the disorder are <u>unusually short.</u>
- Other missing genes regulate ovarian development, which influences sexual characteristics.




Turner syndrome Hypergonadotropic Hypogonadism(female)

- Possible symptoms in young infants include:
- Swollen hands and feet.
- Wide and webbed neck and a low or indistinct hairline.
- A combination of the following symptoms may be seen in older females:
- 1. Absent or incomplete development at puberty.
- 2. A broad chest and widely spaced nipples.
- 3. Drooping eyelids , Dry eyes.
- 4. Infertility.
- 5. No periods (absent menstruation).
- 6. Short height.
- 7. Vaginal dryness.
- 8. Arms that turn out slightly at the elbow.




Kallmann's syndrome (Hypogonadotropic Hypogonadism)

- **□**Happens in females or males.
- □Congenital hormonal condition characterized by the failure of an individual to enter pubert
- □It is a form of **Hypogonadotrophic Hypogonadism** (HH). In particular it is a failure of communication between the hypothalamus and the anterior pituitary glan
- □It results in the sex organs or **gonads** (tester or ovaries) **not maturing** in the usual manner during puberty.



Kallmann's syndrome (Hypogonadism)



Kallmann's syndrome (Hypogonadotropic Hypogonadism)

MALES

FEMALES

PRIMARY SEX CHARACTERISTICS

- * SMALL PENIS & TESTES
- * IMPROPER TESTICULAR DESCENT
- * LOW SPERM COUNT

* AMENORRHEA

(Absence of menstruation)

* OLIGOMENORRHEA

(Irregular menstruation)

SECONDARY SEX CHARACTERISTICS

- * LACK OF FACIAL HAIR
- * LOW MUSCLE
- * NO DEEP VOICE

- * LACK OF BREASTS
- * LACK OF PUBIC HAIR

Non-Reproductive

OSTEOPOROSIS/ OSTEOPENIA

BOTH MALES & FEMALES : INFERTILITY




Kallmann's syndrome (Hypogonadotropic Hypogonadism)


Hypothalamic neurons that are responsible for releasing gonadotropin-releasing hormone (GnRH neurons) fail to migrate into the hypothalamus during embryonic development.

- 1. Failure to start or fully complete puberty in both men and women
- 2. Lack of testicle development in men; size < 3 cm³. The normal range is between 12 and 30 cm³
- **Primary amenorrhea** or failure to start menstruation in women
- 4. Poorly defined secondary sexual characteristics in both men and women.
- 5. Infertility
- 6. Hypogonadotropic hypogonadism (↓LH /↓FSH)
- **7. Congenital** (present from birth)
- 8. Total lack of sense of smell (anosmia) or markedly reduced sense of smell (hyposmia).

Kallmann's syndrome (Hypogonadotropic Hypogonadism)

- 1. Isolated GnRH deficiency.
- Associated with decreased or absent sense of smell (anosmia), and sometimes with other bony, renal and cerebral abnormalities.
- 3. Management is that of secondary hypogonadism.
- 4. Fertility is possible.






Normosmic idiopathic Hypogonadotropic Hypogonadism


- Idiopathic hypogonadotropic hypogonadism (IHH) with normal sense of smell (normosmic IHH)) is a rare genetic disorder caused by an isolated defect in the secretion of GnRH by the hypothalamus or the action of GnRH on the pituitary gonadotrophins.
- 2. Hypogonadism, infertility, absent ,incomplete or partial pubertal maturation.

Diseases	Klinfelter syndrome	Turner syndrome	Kallmman syndrome
Karyotype	Xxy 47	Xo 45	Normal 46 xx or xy
FSH/LH	high	high	low
Testosterone	low	_	Low in males
Estrogen	-	low	Low in females
Treatment	Hormonal replacement	Hormonal replacement	Hormonal replacement Gonadotropins or GNRH pulsatile therapy

Oligospermia or Azoospermia

- These may be secondary to gonadotrophin deficiency and can be corrected by gonadotrophin therapy.
- 2) More often they result from primary testicular diseases, in which case they are rarely treatable.
- 3) Azoospermia with normal testicular size and low FSH levels suggests a vas deferens block, which is sometimes reversible by surgical intervention.







Primary Amenorrhea:

Female patient who has never menstruated-

Is the absence of menstrual bleeding and secondary sexual characteristics (for example, breast development and pubic hair) in a girl by age 13 years.

or

the absence of menstrual bleeding with normal development of secondary sexual characteristics in a girl by age 15 years.

This occurs as a manifestation of delayed puberty or a consequence of anatomical defect of the female reproductive system, such as <u>endometrial hypoplasia</u> or <u>vaginal agenesis</u>

Agenesis: Absence or incomplete development of an <u>organ.</u>

<u>Hypoplasia: the underdevelopment, incomplete development or atrophy of a tissue or organ.</u>

The causes of primary

1-in the absence of secondary sexual characteristics development.

Hypogonadotropic hypogonadism (low FSH and LH levels)

constitutional delay of growth and puberty

Hypergonadotropic hypogonadism (elevated FSH and LH levels)

- gonadal dysgenesis .. <u>Turner syndrome</u>
- premature ovarian failure

2- in the presence of the secondary sexual characteristics development:

Müllerian agenesis (the congenital absence of a vagina and abnormal uterine development)

An imperforate hymen or a transverse vaginal septum

Secondary Amenorrhea:

-cessation of menstruation-

It is defined as the absence of menses for three months in a woman with préviously normal menstruation

The causes of secondary amenorrhea:

1)Physiological

- -Pregnancy
- -Menopause

2) Hypogonadotrophic hypogonadism (hypothalamic/pituitary dysfunction)

Causes of secondary amenorrhea (cont.):

3)Ovarian dysfunction

Polycystic ovarian syndrome Hypergonadotrophic hypogonadism Androgen-secreting tumor

4) Uterine dysfunction

Asherman's syndrome (adhesions and/or fibrosis of the endometrium)

- 5)Premature ovarian failure (premature menopause)
- 6) Hyperprolactenemia
- 7) Hypothyroidism

Clinical assessment History: - Age of the patient

- Date of onset
- Age of menarche
- Sudden or gradual onset
- General health
- Weight changes in recent past:

Weight gain:

may suggest hypothyroidism, Cushing's syndrome or, very rarely, a hypothalamic lesion

Weight loss: of any cause can cause amenorrhea by suppression of gonadotrophins

-anorexia

History:

- Stress (job, lifestyle, exams, relationships).
- -/ Excessive exercise.
- Hirsutism, acne, virilization. (Hirsutism, obesity and long-standing irregular periods suggest polycystic ovarian syndrome)
- Headaches/visual symptoms.
- Drugs.
- Chronic or long-term illnesses.
- Family history of amenorrhea & genetic defects or disorders.
- Past history of pregnancies, gynecological surgery.
- Estrogen deficiency symptoms associated with menopause like: Hot flushes, sweating, Anxiety, Irritability, Emotional lability, Dyspareunia (difficult or painful sexual intercourse).

Physical Examination

•

General health

Body shape and skeletal abnormalities

Weight and height

Hirsutism and acne

Evidence of virilization

Maturity of secondary sexual characteristics

Galactorrhoea

Normality of vagina, cervix and uterus

Approach to evaluation:

- —Once pregnancy has been ruled out, a logical approach to women with either primary or secondary amenorrhea is to consider disorders based upon the levels of control of the menstrual cycle: pituitary, hypothalamus, ovary, and uterus.
- -Determining the site of the defect is important because it determines the appropriate therapeutic regimen.
- -While the most common causes of secondary amenorrhea are likely to be functional hypothalamic amenorrhea or polycystic ovary syndrome (PCOS), disorders with an anatomic or pathologic cause must be ruled out.

Investigations

- •
- **4-Blood tests**: Serum LH, FSH, estradiol, prolactin, testosterone, T3&4, TSH should be measured. High LH, FSH with low estradiol suggest primary ovarian failure.

 Elévated LH, prolactin, testosterone levels with normal estradiol are common in PCOS.

 Low LH, FSH and estradiol suggest hypothalamic or pituitary disease and pituitary MRI is indicated.
- -karyotype should be performed in younger women to exclude mosaic Turner's syndrome.
- -Ultrasonography of the pelvis may be performed to assess the abnormalities.
- -Ovarian biopsy may be needed for primary ovarian failure.

Table 19.25 Amenorrhoea: differential diagnosis and					al diagnosis and investigation	
Hormone results				Possible diagnoses		
LH	FSH	E2	PRL	т		
1	1	1	N	N	Ovarian failure	
					Ovarian dysgenesis* Premature ovarian failure* Steroid biosynthetic defect* (Oophorectomy) (Chemotherapy) Resistant ovary syndrome	
1	1	1	N	N	Gonadotrophin failure	
					Hypothalamic-pituitary disease*	

1	1	1	N	N	Ovarian failure
					Ovarian dysgenesis* Premature ovarian failure* Steroid biosynthetic defect* (Oophorectomy) (Chemotherapy) Resistant ovary syndrome
1	1	1	N	N	Gonadotrophin failure
					Hypothalamic-pituitary disease*

Premature ovarian failure* Steroid biosynthetic defect* (Oophorectomy) (Chemotherapy) Resistant ovary syndrome	Ultrasound of ovary/uterus Laparoscopy/biopsy of ovary HCG stimulation
Gonadotrophin failure	
Hypothalamic-pituitary disease* Kallmann's syndrome/nlHH* Possible hypothalamic causes:	Pituitary MRI if diagnosis unclear Possibly LHRH test Serum free T ₄

/11	7

Exercise-induced amenorrhoea and anorexia* Post-pill amenorrhoea General illness* Hyperprolactinaemia Prolactinoma* Idiopathic hyperprolactinaemia* Hypothyroidism^a Polycystic ovarian disease* Physiological in lactation

Hypothalamic amenorrhoea*

Weight-related amenorrhoea*

See page 955 (hyperprolactinaemia) Serum free T ₄ /TSH Pituitary MRI Other tests for PCOS
Androstenedione, DHEAS

Secondary tests

Karvotype

T/N	N	N

N/T	
N	

Dopamine antagonist drugs NIT Polycystic ovary syndrome* Rarely Cushing's syndrome

HEAS SHBG Ultrasound of ovary Progesterone challenge imaging ovary/adrenal 17a-OH-progesterone

NUL NV. PAR. N N N N

Androgen excess Gonadal or adrenal tumour Congenital adrenal hyperplasia^a

Pregnancy test Examination findings (?EUA) Ultrasound of pelvis Progesterone challenge Hysteroscopy

Possibly full assessment of pituitary function

"These conditions may present as primary amenorrhoea. LH, luteinizing hormone; FSH, follicle-stimulating hormone; E2, oestradiol; PRL, prolactin; T, testosterone; DHEAS, dehydroepiandrosterone sulphate; SHBG, sex hormone-binding globulin; HCG, human chorionic gonadotrophin; LHRH, luteinizing hormone-releasing hormone; nilHL normosmic idiopathic hypogonadotropic hypogonadism; EUA, examination under anaesthesia.

Pregnancy Uterine/vaginal abnormality Imperforate hymen" Absent uterus Lack of endometrium

First of all, the underlying cause should be treated! Wherever possible (e.g. hypothyroidism, low weight, stress, excessive exercise).

Goals — The overall goals of management in women with amenorrhea include:

- -Correcting the underlying pathology, if possible
- -Helping the female patient to achieve fertility, if desired
- -Preventing complications of the disease process (eg, estrogen replacement to prevent osteoporosis)

hirsutism


Female

By Sara aljawamis

Definition of hirsutism


- Hirsutism is when a women grows coarse hair in places they typically either do not grow hair or only have very fine hair (e.g., moustache, chin, torso, back).
- It is a medical sign rather than a disease and may be a sign of a more serious medical condition, especially if it develops well after puberty.






Definition of hirsutism


- Soft vellus hair is normally present all over the body, and this type of hair on the face and elsewhere is normal and not sex hormone dependent.
- While terminal (coarse) hair in the beard, moustache, breast, chest, axilla, abdominal midline, pubic and thigh areas is sex hormone dependent, and any excess hair in these regions is a marker of Hirsutism (increased ovarian or adrenal androgen production, most commonly PCOS)




Pathophysiology

- The number of hair follicles does not change over an individual's lifetime, but the follicle size and type of hair can change in response to numerous factors, particularly androgens.
- Depending upon the <u>body site</u> hormonal regulation plays an important role in the hair growth cycle.
- Androgens increase hair follicle size, hair fiber diameter, and the proportion of time terminal hairs spend in the <u>anagen</u> phase.









Causes

- 1) an increased level of androgens, the male hormones.
- 2) an oversensitivity of hair follicles to androgens. Male hormones such as testosterone stimulate hair growth, increase <u>size</u> and <u>intensify</u> the growth and <u>pigmentation</u> of hair.




Causes



- conditions that may increase a woman's normally low level of male hormones:
- 1- Polycystic ovary syndrome , <u>PCOS</u>, (the most common)
- 2- Congenital adrenal hyperplasia, in turn mostly caused by 21-α hydroxylase deficiency
- 3- Cushing's disease
- 4- Growth hormone excess (Acromegaly)
- 5- Tumors in the ovaries
- 6- adrenal gland (cancer), Von Hippel-Lindau

- 7- Insulin resistance/ hyperinsulinemia
- 8- Stromal Hyperthecosis
- 9- Obesity
- 10- latrogenic use of drugs like Tetrahydrogestrinone
- 11- Adverse effect of Phenytoin
- 12- idiopathic hirsuitism: Hirsutism with no identifiable cause in a women with no other signs of virilization and with normal menstrual cycles, hormone levels and weight.



 should be distinguished from hypertrichosis which is generalized excessive terminal hair growth that affect both men and women that doesn't follow androgen induced pattern

Investigation s

Serum total testosterone

Other androgens.

17α-Hydroxyprogesterone

Gonadotropin levels

Oestrogen levels.

Ovarian ultrasound

Serum prolactin

 Hirsutism may be the initial and possibly only sign of androgen excess, the cutaneous manifestations of which may also include acne and male-pattern balding (androgenetic alopecia).

Table 3. Treatment of hirsutism

Medications

Birth control pills

Androgen receptor blockers

Spironolactone

Flutamide

Glucocorticosteroids

Dexamethasone

Prednisone

Methylprednisolone

Enzyme inhibitors

Finasteride

GnRH analogs

Cosmetic treatments

Shaving

Eflornithine cream

Waxing

Bleaching

Plucking

Depilatory agents


Electrolysis


Laser


POLYCYSTIC OVARY SYNDROME (PCOS)


OVERVIEW OF CAUSES, RISK FACTORS, ASSOCIATED CONDITIONS, SIGNS & SYMPTOMS, DIAGNOSTIC METHODS AND TREATMENTS.

Leen Jalal Damra Group D33









@ MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, ALL RIGHTS RESERVED.


PATHOPHYSIOLOGY

In PCOS the ovaries produce <u>too much</u> <u>testosterone</u> "male hormone", normally the ovaries produce very small amounts, but in PCOS, they make more.

About once a month, a woman's ovaries are supposed to make a "follicle" As the follicle grows, it makes hormones. Then it releases an egg "ovulation"

But in women with PCOS,

- 1) the ovary makes many small follicles instead of one big one.
- 2) Hormone levels can get out of balance.




3) avulation doesn't hannen every month the way

PATHOPHYSIOLOGY

It is important to appreciate that PCOS is a syndrome, not a disease, reflecting multiple potential etiologies.

What stimulates the ovaries to produce excessive amounts of male hormones (androgens), particularly testosterone, either one or a combination of the following:

- 1) Luteinizing hormone (LH) by the anterior pituitary gland through high levels of insulin in the blood (hyperinsulinemia) in women whose ovaries are sensitive to this stimulus
- 2) Alternatively or as well, reduced □ levels of sex-hormone binding globulin can result in increased free androgens.




CLINICAL FEATURE S?

Polycystic ovarian syndrome is a condition that can cause women have:

- menstrual irregularity (Delayed menarche, Oligomenorrhea, Amenorrhea).
- Hyperandrogenism (Acne, Hirsutism, Hair loss).
- Polycystic ovaries

The condition can also make it <u>hard to get pregnant</u> without medical help, <u>it's the most common cause of infertility</u>, due to anovulatory cycles.



INCIDENCE

-Most common endocrinological disorder in reproductive-age women worldwide.

Prevalence estimated to be anywhere between 5-15%

CAUSE

Considerable evidence suggests that it arises as a complex trait with contributions from both heritable and uninheritable intrauterine and extrauterine factors, among which insulin resistance and obesity are most common

This ovarian dysfunction is unique: it appears to be intrinsic and is characterized by abnormal ovarian steroidogenesis and folliculogenesis that are manifested clinically by androgen excess and anovulation.

RISK/ ASSOCIATE D FACTORS

1) Genetics

- Monozygous twins with PCOS
- First-degree relatives with PCOS
- 2) Environmental influences
- 3) Obesity
- Pre-pubertal
- 4) Early-onset menarche
- 5) Large/small for gestational age
- 6) Valproic acid use
- 7) Fetal androgen exposure (?)

PCOS ASSOCIATED CO-MORBIDITIES

Obesity and metabolic syndrome

Impaired glucose tolerance & Type-2 Diabetes

Endometrial cancer

Infertility (anovulation)

Obstructive Sleep Apnea


Depression & Anxiety

Cardiovascular Disease Non-alcoholic fatty liver disease (NAFLD)

DIAGNOSI S

All conditions that mimic polycystic ovarian syndrome (PCOS) should be ruled out before a diagnosis of PCOS is confirmed.

Over the past 25 years, internationally accepted diagnostic criteria have been developed for adults based on various combinations of otherwise unexplained hyperandrogenism, anovulation, and a polycystic ovary. To diagnose PCOS you must have 2 out of 3 "Rotterdam criteria".



TESTS SHOULD BE DONE

Tests are based on age, symptoms, and individual situation.

Possible tests include:

serum total testosterone, other androgens (androstenedione and dehydroepiandrosterone sulphate). SHBG levels are often low (due to high insulin levels), leading to high free androgen levels.

17 a-hydroxyprogesterone

Gonadotropin levels

Estrogen levels

Serum prolactin

Insulin and glucose levels

A pregnancy test if there is missed period.

Pelvic ultrasound – uterus and ovaries.

SCRENING AND INVESTIGATIO NS

The Royal College of Obstetricians and Gynecologists (RCOG) recommends the following baseline screening tests for women with (PCOS):

- 1-Thyroid function tests, to exclude Hypothyroidism
- 2-Serum prolactin levels, to exclude hyperprolactinemia
- 3-Free androgen index (defined as total testosterone divided by sex hormone binding globulin [SHBG] × 100, to give a calculated free testosterone level)
- 4-Any cause of "adrenal hyper-functioning" test for Cushing syndrome, adrenal hyperplasia, serum 17-hydroxyprogesterone levels.

IMAGING

The syndrome acquired its most widely used name due to the common sign on ultrasound examination of multiple (poly) ovarian cysts.

These "cysts" are actually immature follicles, not cysts.


The follicles have developed from primordial follicles, but the development has stopped ("arrested") at an early antral stage due to the disturbed ovarian function.

The follicles may be oriented along the ovarian periphery, appearing as a 'string of pearls' on ultrasound examination.

If the patient tests revealed high testosterone level + rule out other causes of amenorrhea, Hirsutism, infertility Etc.

Ultrasound (transabdominal and/or transvaginal ultrasonography): bilateral enlarged ovaries, multiple small follicles and increased stromal echogenicity.

If you suspected a tumor then use CT or MRI.



TREATMENT GOALS

The overall goals of therapy of women with PCOS include:

Amelioration of hyperandrogenic features (hirsutism, acne, scalp hair loss)

Management of underlying metabolic abnormalities and reduction of risk factors for type 2 diabetes and cardiovascular disease

Prevention of endometrial hyperplasia and carcinoma, which may occur as a result of chronic anovulation

Contraception for those not pursuing pregnancy, as women with Oligomenorrhea ovulate intermittently and unwanted pregnancy may occur.


Ovulation induction for those pursuing pregnancy.

LIFESTYLE CHANGES

Diet and exercise for weight reduction are the first step for overweight and obese women with PCOS. For improving insulin resistance and hyperandrogenism.

In addition, there appear to be reproductive benefits as well.

TREATMENT METHODS



Women who DON'T want to get pregnant

Women who DO want to get pregnan

TREATMENTS CON.

Birth control pills – the main treatment for PCOS. The pills don't cure the condition. But they can improve many of its symptoms, like irregular periods, acne, and facial hair. It also protect women from cancer of the uterus.

Anti-androgens – These medicines block hormones that cause some PCOS symptoms like acne and facial hair growth. Spironolactone (Aldactone) anti-androgen.

Progestin –hormone to make periods regular, only if taken every month. It also lowers the risk of cancer of the uterus. Medroxyprogesterone (Provera) or natural progesterone (Prometrium).

Metformin (Glucophage) – This help to make periods more regular. But it works only in about half of the women who try it. In women with diabetes, helps keep blood sugar levels normal.

Medicated skin lotion or antibiotics to treat acne.

Laser therapy or electrolysis to remove extra hair

TREATMENT FOR WOMEN NOT PURSUING PREGNANCY

Menstrual dysfunction: Endometrial protection — The chronic anovulation seen in PCOS is associated with an increased risk of endometrial hyperplasia and possibly endometrial cancer.

Combined estrogen-progestin oral contraceptives (COCs) as first-line therapy for menstrual dysfunction and endometrial protection.

Androgen excess:

1) Hirsutism, 2) Choice of oral contraceptive, 3)Antiandrogens — After six months, if the patient is not satisfied with the clinical response to COC monotherapy (for hyperandrogenic symptoms), 4) Acne and androgenetic alopecia.

Metabolic abnormalities:

Obesity — Weight loss, which can restore ovulatory cycles and improve metabolic risk, is the first-line intervention for most women. Weight reduction/Bariatric surgery

Insulin resistance/type 2 diabetes — Several drugs, including <u>biguanides</u> (<u>metformin</u>) and thiazolidinediones (<u>pioglitazone</u>, rosiglitazone), can reduce insulin levels in women with PCOS.

TREATMENT FOR WOMEN PURSUING PREGNANCY

Weight loss— For anovulatory women with PCOS who are overweight or obese, we suggest weight loss prior to initiating ovulation induction therapy.

In vitro fertilization — If weight loss, ovulation induction with medications, and/or laparoscopic ovarian laser electrocautery are unsuccessful, the next step is in vitro fertilization

Ovulation induction medications now we suggest letrozole as first-line therapy over clomiphene citrate,

Clomiphene citrate had been the first-line drug for this population for many years, with metformin used as an alternative. However, both clomiphene and metformin appear to be less effective for live birth rates than letrozole

Laparoscopic surgery — In the past, wedge resection of the ovaries was a standard treatment for infertility in women with PCOS.

Resources

Davidson's Principles and Practice of Medicine Kumar and Clark's Clinical Medicine Costanzo Physiology UpToDate

THANK YOU